<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-159958" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Canagliflozin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khalid</surname>
            <given-names>Zoha</given-names>
          </name>
          <aff>St Johns University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Zoha Khalid declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-159958.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Canagliflozin, approved by the Food and Drug Administration (FDA) in 2013, belongs to a class of medications known as sodium-glucose cotransporter 2 (SGLT2) inhibitors.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Type 2 diabetes mellitus (T2DM): SGLT2 inhibitors such as canagliflozin in adjunct with diet and exercise are effective antihyperglycemic agents.<xref ref-type="bibr" rid="article-159958.r1">[1]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Reducing the risk of major cardiovascular events: Canagliflozin is approved to reduce major cardiovascular events such as stroke, nonfatal&#x000a0;myocardial infarction, and cardiovascular death in adults who have been diagnosed with T2DM and have a known history of cardiovascular diseases.<xref ref-type="bibr" rid="article-159958.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diabetic kidney disease: The FDA approved canagliflozin to reduce the risk of&#x000a0;diabetic kidney disease&#x000a0;and end-stage kidney disease in 2019.<xref ref-type="bibr" rid="article-159958.r3">[3]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Heart failure: In 2019, the FDA approved canagliflozin to reduce the risk of hospitalizations associated with heart failure in diabetic nephropathy.<xref ref-type="bibr" rid="article-159958.r4">[4]</xref><xref ref-type="bibr" rid="article-159958.r5">[5]</xref>&#x000a0;A recent study demonstrated that canagliflozin&#x000a0;reduces albuminuria progression and&#x000a0;increases albuminuria regression.<xref ref-type="bibr" rid="article-159958.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Weight loss&#x000a0;<xref ref-type="bibr" rid="article-159958.r7">[7]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Non-alcoholic fatty liver diseases (NAFLD)&#x000a0;<xref ref-type="bibr" rid="article-159958.r8">[8]</xref><xref ref-type="bibr" rid="article-159958.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-159958.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>In healthy individuals, glucose in blood circulation is filtered through the renal glomerulus, reabsorbed in the proximal tubules, and then released back into circulation. Glucose reabsorption in the renal tubules is due to&#x000a0;2 glucose transporters: sodium-glucose co-transporter 1 and 2 (SGLT1 and SGLT2). Diabetic patients often have increased expression of SGLT2, which causes elevated renal glucose reabsorption and the presence of glucose in the plasma.<xref ref-type="bibr" rid="article-159958.r10">[10]</xref></p>
        <p>SGLT2 is primarily responsible for reabsorbing 90% of the glucose&#x000a0;filtered by the kidneys. By competitively and selectively inhibiting SGLT2, canagliflozin reduces renal glucose reabsorption and increases urinary excretion of glucose. Increasing urinary glucose excretion can reduce pressure through an osmotic diuretic effect, loss of calories and body weight, and decreased glucose plasma levels. The mechanism of action is independent of insulin secretion, which makes canagliflozin unique in&#x000a0;its ability to treat patients&#x000a0;with varying stages of diabetes. Canagliflozin possesses unique characteristics distinct from other antihyperglycemic agents and demonstrates the potential for synergistic use with other agents for treating T2DM.</p>
        <p>With&#x000a0;higher selectivity for SGLT2, canagliflozin also inhibits SGLT1 with lower potency.<xref ref-type="bibr" rid="article-159958.r11">[11]</xref>&#x000a0;SGLT1 is expressed in the proximal renal tubules, but the majority is expressed in the lumen of the small intestine, which allows for the reabsorption of glucose and galactose. After being orally administered, canagliflozin can effectively inhibit SGLT1 in the small intestine, decrease intestinal glucose absorption, and lower postprandial glucose levels. In addition to being found in the small intestine, SGLT1 is also found in cardiac myocytes and plays a role in cardiovascular benefits from SGLT2 inhibitors.<xref ref-type="bibr" rid="article-159958.r12">[12]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;The absolute mean oral bioavailability of canagliflozin is 65%. Peak plasma concentrations are achieved 1 to 2 hours after oral administration. Steady-state concentrations are typically achieved after 4 to 5 days of daily oral therapy within 100 to 300 mg of canagliflozin. Food such as high-fat meals do not affect the bioavailability of canagliflozin; it can be taken with or without food. With the potential to reduce postprandial glucose excursions, canagliflozin&#x000a0;is recommended before the day's first meal.&#x000a0;</p>
        <p><bold>Distribution:</bold>&#x000a0;Canagliflozin has a high binding affinity to proteins in plasma, mainly albumin (99%). Additionally, canagliflozin has extensive tissue distribution with a steady-state volume of 83.5&#x000a0;L based on a single intravenous (IV) infusion in healthy individuals.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Canagliflozin is extensively metabolized through O-glucuronidation in the liver by uridine&#x000a0;diphosphate-glucuronosyltransferase enzymes, primarily UGTA19 and UGTB24, into inactive O-glucuronide metabolites M7 and M5.<xref ref-type="bibr" rid="article-159958.r13">[13]</xref>&#x000a0;CYP3A4 metabolism of canagliflozin is minimal (7%).</p>
        <p><bold>Excretion:</bold> The terminal half-life of canagliflozin is 10.6&#x000a0;hours when administered at a dose of 100 mg, and it increases to 13.1&#x000a0;hours when the dose is increased to 300 mg. After a single radiolabeled dose, canagliflozin is excreted in the feces and urine. In the feces, it is excreted 41.5% as the unchanged radiolabeled drug, 7% as a hydroxylated metabolite, and 3.2% as an O-glucuronide metabolite. When excreted in the urine, only 33% of the ingested radiolabeled dose is measured in the urine as O-glucuronide metabolites.<xref ref-type="bibr" rid="article-159958.r13">[13]</xref>&#x000a0;Less than 1% is excreted in the urine in the form of an unchanged drug.</p>
      </sec>
      <sec id="article-159958.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths </bold>
</p>
        <p>Canagliflozin dosage formulations are available in oral tablets of 100 mg and 300 mg for the treatment of T2DM. Canagliflozin is not recommended for patients who are diagnosed with type 1 diabetes mellitus (T1DM). Canagliflozin is administered preferably before the first meal of the day.<xref ref-type="bibr" rid="article-159958.r11">[11]</xref>&#x000a0;Before initiating therapy,&#x000a0; hypovolemia should be corrected if present. If the patient is on concurrent treatment&#x000a0;with insulin or insulin secretagogues (sulfonylureas, meglitinides), a dose reduction of these medications should be considered to avoid the risk of hypoglycemia.&#x000a0;</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>T2DM: 100 mg orally daily before the first meal of the day; can increase the&#x000a0;dosage&#x000a0;to 300 mg daily if needed after 4 to 12 weeks to achieve glycemic goals.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Atherosclerotic cardiovascular disease or heart failure: 100 to 300 mg orally daily.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diabetic kidney disease: 100 mg orally daily before the first meal in patients with urinary albumin excretion &#x0003e;300 mg/day.<xref ref-type="bibr" rid="article-159958.r14">[14]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Renal impairment:</bold> Renal function should be evaluated before initiating canagliflozin. Treatment should be avoided for patients on intermittent hemodialysis, peritoneal dialysis, continuous renal replacement therapy (CRRT), and prolonged intermittent renal replacement therapy (PIRRT).<xref ref-type="bibr" rid="article-159958.r15">[15]</xref><xref ref-type="bibr" rid="article-159958.r16">[16]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>estimated glomerular filtration rate (eGFR) &#x02265;60 mL/min/1.73 m<sup>2</sup>:&#x000a0;Clinicians may consider increasing the&#x000a0;dosage to 300 mg orally daily to improve glycemic control&#x000a0;further.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>eGFR of 45 to &#x0003c;60 mL/min/1.73 m<sup>2</sup>: The&#x000a0;dosage&#x000a0;of canagliflozin is limited to 100 mg orally daily.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>eGFR &#x0003c;45 mL/min/1.73 m<sup>2</sup>: Canagliflozin should not be initiated.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>eGFR &#x0003c;30 mL/min/1.73 m<sup>2</sup>: The treatment with canaglifllozin is contraindicated. However, if the patient is already taking canagliflozin and has albuminuria &#x0003e;300 mg per day, they may continue therapy with 100 mg orally daily to reduce the risk of end-stage kidney disease and cardiovascular death.</p>
          </list-item>
        </list>
        <p>
<bold>Hepatic impairment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild to moderate impairment (Child-Pugh class A, B): No adjustment is necessary.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Severe impairment (Child-Pugh class C): Use is not recommended.</p>
          </list-item>
        </list>
        <p><bold>Pregnancy considerations:</bold> Canagliflozin is&#x000a0;not recommended in pregnant women,&#x000a0;especially during the 2nd and 3rd trimesters.<xref ref-type="bibr" rid="article-159958.r17">[17]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>It is unknown&#x000a0;if canagliflozin passes into the breastmilk; it is 99% plasma protein bound.&#x000a0;However, it is doubtful that it can pass into breast milk.<xref ref-type="bibr" rid="article-159958.r18">[18]</xref>&#x000a0;In clinical trials with lactating rats, data from juvenile rats directly exposed to canagliflozin through lactation showed the risk of&#x000a0;developing kidney issues during maturation. Despite no clear evidence of canagliflozin being passed through human breast milk,&#x000a0;an alternate medication may be preferred&#x000a0;for nursing mothers and infants due to the theoretical risk to the infant's developing kidney.</p>
        <p><bold>Pediatric patients:</bold> Safety and effectiveness for patients&#x000a0;younger than 18 years old have not been established.</p>
        <p><bold>Older patients:</bold> Patients&#x000a0;older&#x000a0;than 65 years have a higher incidence of adverse reactions, particularly with the 300 mg daily dosage.&#x000a0;A more prominent increase in incidence was noted in patients&#x000a0;older than&#x000a0;75 years. Adverse reactions associated with the 300 mg dose included hypotension, postural dizziness, syncope, and dehydration.<xref ref-type="bibr" rid="article-159958.r19">[19]</xref></p>
      </sec>
      <sec id="article-159958.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>In 2017, the FDA gave canagliflozin a box warning,&#x000a0;highlighting the increased risk of leg and foot amputations. As of August 2020, the FDA has removed this box warning associated with canagliflozin and any other medications that include canagliflozin as part of combination therapy.<xref ref-type="bibr" rid="article-159958.r20">[20]</xref></p>
        <p>
<bold>Common Adverse Drug Reactions&#x000a0;of Canagliflozin&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Genital yeast infections in both men and women&#x000a0;<xref ref-type="bibr" rid="article-159958.r21">[21]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Urinary tract infections&#x000a0;<xref ref-type="bibr" rid="article-159958.r22">[22]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Increased urination&#x000a0;<xref ref-type="bibr" rid="article-159958.r22">[22]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Dehydration&#x000a0;<xref ref-type="bibr" rid="article-159958.r23">[23]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Orthostatic hypotension&#x000a0;<xref ref-type="bibr" rid="article-159958.r24">[24]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Increased cholesterol levels (LDL-C)&#x000a0;<xref ref-type="bibr" rid="article-159958.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>UDP-glucuronosyltransferase (UGT) enzyme inducers:&#x000a0;If patients are currently tolerating a 100 mg daily dose of canagliflozin and have an eGFR &#x02265;60 mL/min/1.73 m<sup>2</sup>, consider increasing the&#x000a0;dosage of canagliflozin to 300 mg daily if coadministered with UGT enzyme inducers. UGT enzyme inducers, such as rifampin, phenytoin, phenobarbital, or ritonavir, all work on UGT enzymes such as UGT1A9 and UGT2B4. When coadministered with canagliflozin, medications that induce UGT enzymes decrease the efficacy of canagliflozin. Alternative antihyperglycemic therapy should be considered in patients with an eGFR &#x0003c;45 mL/min/1.73 m<sup>2</sup>.<xref ref-type="bibr" rid="article-159958.r25">[25]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Digoxin: An increase in digoxin's peak drug concentration occurs when used concurrently with canagliflozin 300 mg daily dosing. Patients treated with canagliflozin with concomitant digoxin should be monitored and have the dose adjusted for digoxin accordingly.<xref ref-type="bibr" rid="article-159958.r26">[26]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diuretics:&#x000a0;Canagliflozin results in osmotic diuresis, leading to reduced intravascular volume. Loop diuretics, hydrochlorothiazide, and thiazide-like diuretics are associated with the most significant&#x000a0;increase in volume depletion-related adverse reactions. Concomitant use of canagliflozin with diuretics can increase the risk of dehydration and hypotension, and the dosing of diuretics should be adjusted accordingly.<xref ref-type="bibr" rid="article-159958.r27">[27]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>CYP3A4 inducers:&#x000a0;Medications that induce the CYP3A4 enzyme, such as rifampin, can decrease drug concentrations of canagliflozin. Dose adjustments of canagliflozin may be necessary when coadministered with CYP3A4 inducers.<xref ref-type="bibr" rid="article-159958.r28">[28]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>CYP3A4 inhibitors:&#x000a0;Medications that inhibit the CYP3A4 enzyme, such as ketoconazole, can increase drug concentrations of canagliflozin in the body. This can potentially lead to an increased risk for adverse events associated with canagliflozin.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-159958.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Contraindications</bold>
</p>
        <p>Canagliflozin is contraindicated in individuals with a history of severe hypersensitivity, anaphylaxis, or angioedema to any drug components.<xref ref-type="bibr" rid="article-159958.r29">[29]</xref>&#x000a0;Patients with severe renal impairment (eGFR &#x0003c;30 ml/min), end-stage renal disease (ESRD), or are on dialysis should avoid treatment with canagliflozin due to its ability to increase serum creatinine. In addition to patients with renal impairment, if they are taking medications that interfere with potassium excretion and the renin-angiotensin-aldosterone system (potassium-sparing diuretics or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers [ACEI/ARBs]), they are at a higher risk of developing hyperkalemia.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p><bold>Hypotension:</bold> Canagliflozin can cause symptomatic hypotension and intravascular volume contraction. Patients with impaired renal function (eGFR &#x0003c;60 mL/min/1.73 m<sup>2</sup>), low systolic blood pressure,&#x000a0;who are taking any medications that interfere with the renin-angiotensin-aldosterone system (ACEI/ARBs)&#x000a0; and who are older are at a higher risk of developing hypotension. Before initiating therapy, volume status should be assessed, and patients should be monitored for signs and symptoms.<xref ref-type="bibr" rid="article-159958.r30">[30]</xref></p>
        <p><bold>Ketoacidosis:</bold>&#x000a0;Ketoacidosis is a serious life-threatening emergency that requires urgent hospitalization. Through postmarketing surveillance and clinical trials, reports of ketoacidosis have been identified in patients with&#x000a0;T1DM and&#x000a0;T2DM who received SGLT2 inhibitors like canagliflozin. The risk of developing ketoacidosis is greater with higher doses of canagliflozin. All patients being treated with canagliflozin who present symptoms of severe metabolic acidosis should be assessed for ketoacidosis regardless of blood glucose levels. Ketoacidosis associated with canagliflozin may be present even if glucose levels are &#x0003c;250 mg/dL. If ketoacidosis is suspected, canagliflozin should be immediately discontinued, and treatment should be initiated, which may include insulin, fluid, and carbohydrate replacement. Before initiating therapy with canagliflozin,&#x000a0;clinicians should consider patient risk factors for ketoacidosis, which may include pancreatic insulin deficiency, alcohol abuse, and caloric restriction.<xref ref-type="bibr" rid="article-159958.r31">[31]</xref><xref ref-type="bibr" rid="article-159958.r32">[32]</xref></p>
        <p><bold>Impaired renal function:</bold>&#x000a0;Canagliflozin increases serum creatinine and decreases eGFR. Patients with hypovolemia have a higher risk for impaired renal function. Renal function abnormalities should be closely monitored, especially in those patients with an eGFR &#x0003c;60 mL/min/1.73m<sup>2</sup>.<xref ref-type="bibr" rid="article-159958.r14">[14]</xref></p>
        <p><bold>Hyperkalemia:</bold>&#x000a0;Patients who have moderate renal impairment and concurrently take medications that interfere with the renin-angiotensin-aldosterone system (ACEI/ARBs) are at a higher risk of developing hyperkalemia. Potassium levels should be monitored periodically after starting therapy with canagliflozin. Based on clinical trials, such as the CANVAS program, the rate of hyperkalemia events was comparable between the placebo and canagliflozin.<xref ref-type="bibr" rid="article-159958.r33">[33]</xref></p>
        <p><bold>Urosepsis and pyelonephritis:</bold>&#x000a0;Canagliflozin's primary&#x000a0;mechanism of action works by increasing urinary glucose excretion. Excessive amounts of sugar are being excreted through the urinary tract, which&#x000a0;makes it&#x000a0;a perfect breeding ground for bacteria. Postmarketing reports on canagliflozin have shown significant numbers of severe urinary tract infections, which included pyelonephritis and urosepsis. Patients should be evaluated for signs or symptoms of urinary tract infections and treated promptly based on the clinical discretion of&#x000a0;the&#x000a0;healthcare team.<xref ref-type="bibr" rid="article-159958.r22">[22]</xref></p>
        <p><bold>Genital mycotic infections:</bold>&#x000a0;A high prevalence of genital mycotic infections has been identified in patients being treated with canagliflozin. Patients who have a history of genital mycotic infections and males who are uncircumcised are at a higher risk. Additionally, females who have a history of recurrent infections should be strongly advised to avoid therapy with canagliflozin. Treatment of&#x000a0;genital mycotic infections consists of educating patients on proper hygiene.&#x000a0;In the case of severe infections, patients may take a single dose of an oral antifungal such as fluconazole to resolve symptoms. Mild infections may be managed through self-care, and with appropriate management, alterations to canagliflozin therapy are not necessary.<xref ref-type="bibr" rid="article-159958.r34">[34]</xref></p>
        <p><bold>Hypoglycemia:</bold>&#x000a0;Canagliflozin increases the risk of hypoglycemia when combined with insulin and insulin secretagogues. The doses of insulin and insulin secretagogue-like medications should be reduced to prevent hypoglycemia when used with canagliflozin.</p>
        <p><bold>Bone fracture:</bold>&#x000a0;As early as 12 weeks of therapy with canagliflozin, an increased risk of bone fracture has been noted in patients being treated. Patients should be assessed for risk factors contributing&#x000a0;to bone fractures, such as hyperparathyroidism and increased bone turnover.<xref ref-type="bibr" rid="article-159958.r30">[30]</xref>&#x000a0;Individuals with vitamin D deficiency showed an increased susceptibility to canagliflozin's adverse effects on biomarkers relevant to bone health. Supplementation with vitamin D3 provided protection.<xref ref-type="bibr" rid="article-159958.r35">[35]</xref></p>
        <p><bold>Lower limb amputation:&#x000a0;</bold>Clinical trials, the CANVAS program, have identified a doubled&#x000a0;increased risk of amputation associated with canagliflozin compared to placebo. Amputations were more common in the lower limbs (toe, midfoot, and sometimes the leg) in patients with&#x000a0;T2DM being treated and those&#x000a0;with a prior history of cardiovascular disease. The risk of amputations was observed&#x000a0;at the 100 and 300 mg doses. Before starting therapy with canagliflozin, patient risk factors should be assessed, which can include a history of amputations, peripheral vascular disease, diabetic foot ulcers, and neuropathy. Patients should be closely monitored for signs and symptoms of infection (cellulitis and osteomyelitis), pain or erythema, new tenderness, and sores or ulcers on the lower extremities. If any of these complications occur, canagliflozin should be discontinued immediately. Lastly, all patients should be counseled on preventative foot care for prevention.<xref ref-type="bibr" rid="article-159958.r36">[36]</xref></p>
        <p><bold>Fournier's gangrene: </bold>Multiple cases of Fournier's gangrene, also known as necrotizing fascitis, have been identified through postmarketing surveillance of canagliflozin. This is a rare but severe and life-threatening infection that requires urgent surgical intervention and may cause death if left untreated. Patients treated with canagliflozin who present with pain, tenderness, erythema, swelling in the genital or perianal area, and fever should be assessed for necrotizing fasciitis. If suspected, canagliflozin should be discontinued, and broad-spectrum antibiotics should be started immediately with surgical debridement.&#x000a0;Glucose levels should be closely monitored, and an alternative therapy should be used for glucose control.<xref ref-type="bibr" rid="article-159958.r37">[37]</xref></p>
      </sec>
      <sec id="article-159958.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring parameters for individuals being treated with canagliflozin typically involve a combination of laboratory testing and clinical assessments to ensure medication effectiveness and safety. Treatment guidelines do not provide specific recommendations on the frequency or duration of monitoring. These parameters should be&#x000a0;individualized for each&#x000a0;patient based on a healthcare professional's clinical discretion.</p>
        <p>Since canagliflozin is an antihyperglycemic agent and affects renal glucose absorption, healthcare professionals should regularly check patient's diabetes through regular blood tests (blood sugar levels and HbA1c), renal function, and educate patients on adhering to a prescribed diet alongside adequate exercise. Healthcare professionals should monitor HbA1c twice a year for patients who have stable glycemic control and are meeting treatment end goals. If treatment goals are not met, HbA1c should be monitored quarterly.<xref ref-type="bibr" rid="article-159958.r7">[7]</xref>&#x000a0;For nonpregnant adults, the goal HbA1c should be &#x0003c;7% and a more aggressive approach should be &#x0003c;6.5%. The blood glucose goal before meals (preprandial) should be between 80 and 130 mg/dL, and 1 to 2 hours after meals (postprandial) should be &#x0003c;180 mg/dL.</p>
        <p>Healthcare teams should monitor for risk of adverse events such as risk for lower limb amputation or bone fracture, ketoacidosis, symptomatic hypotension, necrotizing fascitis, pyelonephritis, and genital mycotic infections.&#x000a0;Temporary interruption of canagliflozin is recommended for patients undergoing major surgery or procedures involving prolonged fasting. If possible, clinicians should withhold canagliflozin for at least&#x000a0;3 days before such interventions. After the surgery or procedure is completed and the patient has resumed oral intake and is clinically stable, canagliflozin therapy can be resumed.<xref ref-type="bibr" rid="article-159958.r38">[38]</xref></p>
      </sec>
      <sec id="article-159958.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Canagliflozin overdose and toxicity can increase the risk of hypoglycemia when administered with other diabetic medications. If a patient has severe hypoglycemia, they should self-administer an emergency glucagon kit. Additional symptoms of overdose include severe dehydration, electrolyte imbalances, and constant low blood pressure.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>If an overdose is suspected, it is crucial to seek immediate medical attention and contact emergency services such as the poison control center. Overdose treatment typically consists of supportive care to reverse electrolyte imbalances with fluid replacement and additional supportive measures to manage symptoms.<xref ref-type="bibr" rid="article-159958.r12">[12]</xref>&#x000a0;If&#x000a0;clinicians deem it necessary to remove unabsorbed drug components of canagliflozin, a 4-hour hemodialysis session can remove canagliflozin to negligible levels. Healthcare teams should implement clinical monitoring based on&#x000a0;the patient's health&#x000a0;status. As canagliflozin is highly protein plasma bound, it is not expected to be dialyzable through peritoneal dialysis.</p>
      </sec>
      <sec id="article-159958.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Canagliflozin is an excellent third-line choice of therapy among the multiple options of antihyperglycemic agents for treating T2DM. Combined&#x000a0;with diet and exercise, canagliflozin demonstrates substantial efficacy in controlling blood glucose levels&#x000a0;in T2DM. In addition to benefits for patients with diabetes, canagliflozin is an effective agent in reducing cardiovascular risks such as stroke and has shown notable benefits in lowering the risk of renal complications. Unlike other SGLT2 inhibitors, such as dapagliflozin and empagliflozin, canagliflozin exhibits a comparatively longer half-life, between 10 to 13 hours, permitting daily dosing. Healthcare professionals must have comprehensive knowledge of canagliflozin's indications, contraindications, and potential adverse effects. However, the medication can cause euglycemic diabetic ketoacidosis, especially in patients with a history of pancreatitis. Therefore,&#x000a0;clinicians must monitor for signs or symptoms of dehydration and abnormal kidney function throughout the treatment.</p>
        <p>Canagliflozin use requires collaboration among an interprofessional healthcare team to effectively optimize therapy outcomes. Typically, physicians&#x000a0;or advanced care practitioners will initiate treatment. Pharmacists should diligently monitor for potential drug interactions, such as loop diuretics or rifampin. In addition, pharmacists should also verify dosing and educate patients on common adverse drug reactions. Nurses should assess patient adherence to the medication regimen and offer counseling on medication administration. Both pharmacy and nursing staff should alert a patient's prescriber if they encounter any issues. In cases of overdose, the entire team, especially emergency medicine clinicians, should focus on stabilizing the patient's condition and addressing electrolyte imbalances or signs of dehydration. In a severe case of overdose, collaboration with medical toxicologists, specialized care, and close monitoring in a critical care unit are vital.</p>
        <p>The coordinated interprofessional team approach can significantly improve patient outcomes and ensure effective diabetes management while mitigating adverse effects and associated complications. Compelling evidence from comprehensive clinical trials underscores the importance of utilizing a team-based care approach involving different healthcare fields. This multidisciplinary approach enhances glycemic control and reduces cardiovascular risks in patients taking antihyperglycemic agents&#x000a0;such as canagliflozin.<xref ref-type="bibr" rid="article-159958.r39">[39]</xref></p>
      </sec>
      <sec id="article-159958.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=159958&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=159958">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/159958/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=159958">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-159958.s10">
        <title>References</title>
        <ref id="article-159958.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landgraf</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aberle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Birkenfeld</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Gallwitz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kellerer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Wieland</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nauck</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Therapy of Type 2 Diabetes.</article-title>
            <source>Exp Clin Endocrinol Diabetes</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>127</volume>
            <issue>S 01</issue>
            <fpage>S73</fpage>
            <page-range>S73-S92</page-range>
            <pub-id pub-id-type="pmid">31860927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>de Zeeuw</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fulcher</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Erondu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matthews</surname>
                <given-names>DR</given-names>
              </name>
              <collab>CANVAS Program Collaborative Group</collab>
            </person-group>
            <article-title>Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Aug</month>
            <day>17</day>
            <volume>377</volume>
            <issue>7</issue>
            <fpage>644</fpage>
            <page-range>644-657</page-range>
            <pub-id pub-id-type="pmid">28605608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mende</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.</article-title>
            <source>Adv Ther</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>148</fpage>
            <page-range>148-164</page-range>
            <pub-id pub-id-type="pmid">34846711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spertus</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Birmingham</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Nassif</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Damaraju</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Abbate</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lanfear</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kosiborod</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.</article-title>
            <source>Nat Med</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>809</fpage>
            <page-range>809-813</page-range>
            <pub-id pub-id-type="pmid">35228753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>R&#x000e5;dholm</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Figtree</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>de Zeeuw</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fulcher</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matthews</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.</article-title>
            <source>Circulation</source>
            <year>2018</year>
            <month>Jul</month>
            <day>31</day>
            <volume>138</volume>
            <issue>5</issue>
            <fpage>458</fpage>
            <page-range>458-468</page-range>
            <pub-id pub-id-type="pmid">29526832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tobe</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Mavrakanas</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Bajaj</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tangri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Slee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Neuen</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Rapattoni</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ang</surname>
                <given-names>FG</given-names>
              </name>
            </person-group>
            <article-title>Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials.</article-title>
            <source>Diabetes Care</source>
            <year>2024</year>
            <month>Mar</month>
            <day>01</day>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>501</fpage>
            <page-range>501-507</page-range>
            <pub-id pub-id-type="pmid">38252809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heerspink</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Perkins</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Fitchett</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Husain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cherney</surname>
                <given-names>DZ</given-names>
              </name>
            </person-group>
            <article-title>Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.</article-title>
            <source>Circulation</source>
            <year>2016</year>
            <month>Sep</month>
            <day>06</day>
            <volume>134</volume>
            <issue>10</issue>
            <fpage>752</fpage>
            <page-range>752-72</page-range>
            <pub-id pub-id-type="pmid">27470878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bellanti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lo Buglio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dobrakowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kasperczyk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kasperczyk</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Serviddio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vendemiale</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.</article-title>
            <source>World J Gastroenterol</source>
            <year>2022</year>
            <month>Jul</month>
            <day>14</day>
            <volume>28</volume>
            <issue>26</issue>
            <fpage>3243</fpage>
            <page-range>3243-3257</page-range>
            <pub-id pub-id-type="pmid">36051336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gautam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Doneria</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nigam</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Effects of Canagliflozin on Abnormal Liver Function Tests in Patients of Type 2 Diabetes with Non-Alcoholic Fatty Liver Disease.</article-title>
            <source>J Assoc Physicians India</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>66</volume>
            <issue>8</issue>
            <fpage>62</fpage>
            <page-range>62-66</page-range>
            <pub-id pub-id-type="pmid">31324087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenthal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Meininger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ways</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Polidori</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vercruysse</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Balis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bull</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Prospero</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rothenberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Canovatchel</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Demarest</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>1358</volume>
            <fpage>28</fpage>
            <page-range>28-43</page-range>
            <pub-id pub-id-type="pmid">26305874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deeks</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Scheen</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Canagliflozin: A Review in Type 2 Diabetes.</article-title>
            <source>Drugs</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>77</volume>
            <issue>14</issue>
            <fpage>1577</fpage>
            <page-range>1577-1592</page-range>
            <pub-id pub-id-type="pmid">28836175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jakher</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>Canagliflozin review - safety and efficacy profile in patients with T2DM.</article-title>
            <source>Diabetes Metab Syndr Obes</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>209</fpage>
            <page-range>209-215</page-range>
            <pub-id pub-id-type="pmid">30787627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devineni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Polidori</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>54</volume>
            <issue>10</issue>
            <fpage>1027</fpage>
            <page-range>1027-41</page-range>
            <pub-id pub-id-type="pmid">26041408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jardine</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bompoint</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Heerspink</surname>
                <given-names>HJL</given-names>
              </name>
              <name>
                <surname>Charytan</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bull</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Capuano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>de Zeeuw</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Yavin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zinman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Meininger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <collab>CREDENCE Trial Investigators</collab>
            </person-group>
            <article-title>Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Jun</month>
            <day>13</day>
            <volume>380</volume>
            <issue>24</issue>
            <fpage>2295</fpage>
            <page-range>2295-2306</page-range>
            <pub-id pub-id-type="pmid">30990260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheen</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>54</volume>
            <issue>7</issue>
            <fpage>691</fpage>
            <page-range>691-708</page-range>
            <pub-id pub-id-type="pmid">25805666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khurana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vaidyanathan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marathe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mehrotra</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sahajwalla</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Zineh</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Canagliflozin use in patients with renal impairment-Utility of quantitative clinical pharmacology analyses in dose optimization.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>647</fpage>
            <page-range>647-56</page-range>
            <pub-id pub-id-type="pmid">25612234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ElSayed</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Aleppo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aroda</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Bannuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Bruemmer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Hilliard</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Kahan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Prahalad</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pratley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Jeffrie Seley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stanton</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Gabbay</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>on behalf of the American Diabetes Association</surname>
              </name>
            </person-group>
            <article-title>15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2023.</article-title>
            <source>Diabetes Care</source>
            <year>2023</year>
            <month>Jan</month>
            <day>01</day>
            <volume>46</volume>
            <issue>Suppl 1</issue>
            <fpage>S254</fpage>
            <page-range>S254-S266</page-range>
            <pub-id pub-id-type="pmid">36507645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <chapter-title>Canagliflozin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>6</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">29999683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elmore</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Baggett</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Skelley</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes.</article-title>
            <source>Consult Pharm</source>
            <year>2014</year>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>335</fpage>
            <page-range>335-46</page-range>
            <pub-id pub-id-type="pmid">24849690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plosker</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.</article-title>
            <source>Drugs</source>
            <year>2014</year>
            <month>May</month>
            <volume>74</volume>
            <issue>7</issue>
            <fpage>807</fpage>
            <page-range>807-24</page-range>
            <pub-id pub-id-type="pmid">24831734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El Hage</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kashyap</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus.</article-title>
            <source>J Prim Care Community Health</source>
            <year>2019</year>
            <season>Jan-Dec</season>
            <volume>10</volume>
            <fpage>2150132719895188</fpage>
            <pub-id pub-id-type="pmid">31894715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dave</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Schneeweiss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fralick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patorno</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.</article-title>
            <source>Ann Intern Med</source>
            <year>2019</year>
            <month>Aug</month>
            <day>20</day>
            <volume>171</volume>
            <issue>4</issue>
            <fpage>248</fpage>
            <page-range>248-256</page-range>
            <pub-id pub-id-type="pmid">31357213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saisho</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?</article-title>
            <source>Diseases</source>
            <year>2020</year>
            <month>May</month>
            <day>11</day>
            <volume>8</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">32403420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weir</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Januszewicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Vijapurkar</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kline</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meininger</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>875</fpage>
            <page-range>875-82</page-range>
            <pub-id pub-id-type="pmid">25329038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devineni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vaccaro</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Curtin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mamidi</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Ariyawansa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stieltjes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wajs</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Di Prospero</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Rothenberg</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.</article-title>
            <source>Int J Clin Pharmacol Ther</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-28</page-range>
            <pub-id pub-id-type="pmid">25407255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheen</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>53</volume>
            <issue>4</issue>
            <fpage>295</fpage>
            <page-range>295-304</page-range>
            <pub-id pub-id-type="pmid">24420910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Arnott</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Neuen</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Heersprink</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Baldridge</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Figtree</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jardine</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Huffman</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.</article-title>
            <source>ESC Heart Fail</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>1482</fpage>
            <page-range>1482-1493</page-range>
            <pub-id pub-id-type="pmid">33595905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mamidi</surname>
                <given-names>RNVS</given-names>
              </name>
              <name>
                <surname>Dallas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sensenhauser</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Scheers</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Verboven</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cuyckens</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leclercq</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Snoeys</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2017</year>
            <month>May</month>
            <volume>83</volume>
            <issue>5</issue>
            <fpage>1082</fpage>
            <page-range>1082-1096</page-range>
            <pub-id pub-id-type="pmid">27862160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r29">
          <label>29</label>
          <element-citation publication-type="book">
            <source>Canagliflozin (Invokana) for Type 2 Diabetes Mellitus [Internet]</source>
            <publisher-name>Canadian Agency for Drugs and Technologies in Health</publisher-name>
            <publisher-loc>Ottawa (ON)</publisher-loc>
            <year>2015</year>
            <month>09</month>
            <pub-id pub-id-type="pmid">26962611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moseley</surname>
                <given-names>KF</given-names>
              </name>
            </person-group>
            <article-title>Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits.</article-title>
            <source>Curr Osteoporos Rep</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>439</fpage>
            <page-range>439-448</page-range>
            <pub-id pub-id-type="pmid">32710428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blau</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tella</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Rother</surname>
                <given-names>KI</given-names>
              </name>
            </person-group>
            <article-title>Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.</article-title>
            <source>Diabetes Metab Res Rev</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">28736981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burke</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Harpe</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.</article-title>
            <source>Pharmacotherapy</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>187</fpage>
            <page-range>187-194</page-range>
            <pub-id pub-id-type="pmid">27931088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weir</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Slee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Balis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Zeeuw</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program.</article-title>
            <source>Clin Kidney J</source>
            <year>2021</year>
            <month>May</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>1396</fpage>
            <page-range>1396-1402</page-range>
            <pub-id pub-id-type="pmid">34221371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Engelhardt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosselli</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors.</article-title>
            <source>Ann Pharmacother</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>55</volume>
            <issue>4</issue>
            <fpage>543</fpage>
            <page-range>543-548</page-range>
            <pub-id pub-id-type="pmid">32808541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shahidzadeh Yazdi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Streeten</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Whitlatch</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Montasser</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Beitelshees</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2024</year>
            <month>Jan</month>
            <day>18</day>
            <volume>109</volume>
            <issue>2</issue>
            <fpage>e646</fpage>
            <page-range>e646-e656</page-range>
            <pub-id pub-id-type="pmid">37738423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papadokostaki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rizos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tigas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liberopoulos</surname>
                <given-names>EN</given-names>
              </name>
            </person-group>
            <article-title>Canagliflozin and Amputation Risk: Evidence So Far.</article-title>
            <source>Int J Low Extrem Wounds</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-26</page-range>
            <pub-id pub-id-type="pmid">31698973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elbeddini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gallinger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Davey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brassard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gazarin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Plourde</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Aly</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A Case of Fournier's Gangrene in a Patient Taking Canagliflozin for the Treatment of Type II Diabetes Mellitus.</article-title>
            <source>Am J Case Rep</source>
            <year>2020</year>
            <month>Feb</month>
            <day>24</day>
            <volume>21</volume>
            <fpage>e920115</fpage>
            <pub-id pub-id-type="pmid">32089542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ideno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shiga</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Motoyasu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Noguchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yoshikawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hoshijima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hyuga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shishii</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nagai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Higashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ouchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kuratani</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports.</article-title>
            <source>J Anesth</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>465</fpage>
            <page-range>465-473</page-range>
            <pub-id pub-id-type="pmid">36849747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159958.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charytan</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Jardine</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lambers Heerspink</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>de Zeeuw</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zinman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Di Tanna</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Arnott</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.</article-title>
            <source>BMJ Open Diabetes Res Care</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>11</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">37311602</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
